 |
|
The Cardiovascular, Pulmonary, and Ocular Hypotensive Effects of 0.2% Brimonidine
John R. Nordlund, MD, PhD;
Louis R. Pasquale, MD;
Alan L. Robin, MD;
Michael T. Rudikoff, MD;
Joan Ordman, MD;
Kuankuan S. Chen, MS;
John Walt, MBA
Arch Ophthalmol. 1995;113(1):77-83.
Abstract
| |
Objective
To compare the cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine tartrate with those of 0.5% timolol maleate, 0.25% betaxolol suspension, and brimonidine vehicle.
Design and Patients
A single-center, double-masked, randomized, crossover study of 24 young, healthy men.
Interventions
Baseline heart rate, blood pressure, respiratory rate, and intraocular pressure were recorded at hour 0. At hour 2, heart rate, blood pressure, respiratory rate, and forced expiratory volume in 1 second were measured and a 15-minute treadmill test performed. Hour 0 measurements were repeated at hour 4. On four subsequent visits, we instilled one drop of a study medication into each eye after the baseline measurements at hour 0.
Results
Timolol reduced resting (–5.3 to –6.5 beats/min; P .004) and exercise-induced heart rate (–4.3 to –13.6 beats/min; P.022) compared with brimonidine, betaxolol suspension, and brimonidine vehicle. At hour 4, brimonidine reduced resting systolic blood pressure compared with all other study medications (–5.2 to –7.3 mm Hg; P.024). Timolol reduced systolic blood pressure during exercise and brimonidine reduced systolic blood pressure during recovery more than betaxolol suspension and brimonidine vehicle (–5.1 to –7.7 mm Hg; P.033; and –5.4 to –6.0 mm Hg; P.002, respectively). Mean respiratory rate and forced expiratory volume in 1 second were not significantly altered by any study medication. At hour 4, brimonidine lowered intraocular pressure as well as timolol and better than betaxolol suspension (–1.9 mm Hg; P<.001) or brimonidine vehicle (–1.8 mm Hg; P<.001).
Conclusions
The cardiopulmonary effects of 0.2% brimonidine were limited to a slight reduction in systolic blood pressure during recovery from exercise and at 4 hours after instillation. The ocular hypotensive effect of brimonidine was comparable to that of timolol and greater than that of betaxolol suspension in this patient population.
Author Affiliations
From The Wilmer Ophthalmological Institute (Drs Nordlund, Pasquale, and Robin), The School of Hygiene and Public Health (Dr Robin), and the Department of Medicine (Drs Rudikoff and Ordman), The Johns Hopkins University School of Medicine, Baltimore, Md, and Allergan Inc, Irvine, Calif (Ms Chen and Mr Walt).; Dr Nordlund is currently with the Department of Ophthalmology, University of Virginia, Charlottesville, and Dr Pasquale, the Division of Ophthalmology, Brigham and Women's Hospital, Boston, Mass. Drs Nordlund, Pasquale, Robin, Rudikoff, and Ordman do not have any proprietary interest in Allergan Inc, or any of the study medications.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension
Sharpe et al.
Br J Ophthalmol 2004;88:953-956.
ABSTRACT
| FULL TEXT
Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma
Liu et al.
Br J Ophthalmol 2002;86:1236-1239.
ABSTRACT
| FULL TEXT
Effect of Brimonidine Tartrate on Ocular Hemodynamic Measurements
Lachkar et al.
Arch Ophthalmol 1998;116:1591-1594.
ABSTRACT
| FULL TEXT
Medical Management of Glaucoma
Alward
NEJM 1998;339:1298-1307.
FULL TEXT
{beta}-Blocker-Induced Complications and the Patient With Glaucoma: Newer Treatments to Help Reduce Systemic Adverse Events
Stewart and Garrison
Arch Intern Med 1998;158:221-226.
FULL TEXT
Maximal Medical Therapy for Glaucoma
Zimmerman and Fechtner
Arch Ophthalmol 1997;115:1579-1580.
ABSTRACT
A 1-Year Study of Brimonidine Twice Daily in Glaucoma and Ocular Hypertension: A Controlled, Randomized, Multicenter Clinical Trial
Schuman et al.
Arch Ophthalmol 1997;115:847-852.
ABSTRACT
Effects of Brimonidine on Aqueous Humor Dynamics in Human Eyes
Toris et al.
Arch Ophthalmol 1995;113:1514-1517.
ABSTRACT
|
